In the last three months, 4 analysts have published ratings on Adaptive Biotechnologies (NASDAQ:ADPT), offering a diverse range of perspectives from bullish to bearish. The table below provides a ...
The market expects Adaptive Biotechnologies (ADPT) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2025. This widely-known ...
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.22 per share a year ago. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results